NEPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NEPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Nephros's share price is $2.19. Nephros's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.37. Hence, Nephros's PS Ratio for today is 1.60.
The historical rank and industry rank for Nephros's PS Ratio or its related term are showing as below:
During the past 13 years, Nephros's highest PS Ratio was 15.00. The lowest was 0.92. And the median was 6.35.
Nephros's Revenue per Sharefor the three months ended in Dec. 2023 was $0.31. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.37.
During the past 12 months, the average Revenue per Share Growth Rate of Nephros was 41.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 13.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 4.50% per year. During the past 10 years, the average Revenue per Share Growth Rate was 8.50% per year.
During the past 13 years, Nephros's highest 3-Year average Revenue per Share Growth Rate was 47.10% per year. The lowest was -61.00% per year. And the median was -6.80% per year.
The historical data trend for Nephros's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nephros Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
PS Ratio | Get a 7-Day Free Trial | 7.26 | 9.10 | 5.78 | 1.19 | 2.52 |
Nephros Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
PS Ratio | Get a 7-Day Free Trial | 1.19 | 0.96 | 1.31 | 1.13 | 2.52 |
For the Medical Instruments & Supplies subindustry, Nephros's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Nephros's PS Ratio distribution charts can be found below:
* The bar in red indicates where Nephros's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Nephros's PS Ratio for today is calculated as
PS Ratio | = | Share Price | / | Revenue per Share (TTM) |
= | 2.19 | / | 1.371 | |
= | 1.60 |
Nephros's Share Price of today is $2.19.
Nephros's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.37.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PS Ratio | = | Market Cap | / | Revenue |
The Revenue here is for the trailing 12 months.
Nephros (NAS:NEPH) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
Be Aware
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Thank you for viewing the detailed overview of Nephros's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Banks Robert R. Jr. | director, officer: President and CEO | C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079 |
Judy Krandel | officer: Chief Financial Officer | 320 W. 37TH STREET, 13TH FLOOR, NEW YORK NY 10018 |
Joseph Michael Harris | director | C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079 |
Wesley S. Lobo | officer: Chief Marketing Officer | C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079 |
Tom Gwydir | director | C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079 |
Andrew Astor | officer: Chief Financial Officer | 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079 |
Charles E Davidson | director, 10 percent owner | C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401 |
Wexford Capital Lp | director, 10 percent owner | 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830 |
Joseph Jacobs | director, 10 percent owner | C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401 |
Wexford Gp Llc | director, 10 percent owner | C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH CT 33401 |
Oliver J. Spandow | director | C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079 |
Daniel S. D'agostino | officer: Chief Financial Officer | C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079 |
Daron Evans | director, officer: President and CEO | C/O NEPHROS, INC., 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079 |
Alisa Lask | director | C/O 380 LACKAWANNA PLACE, SOUTH ORANGE NJ 07079 |
Paul A Mieyal | director | C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-16-2022
By GuruFocusNews GuruFocusNews • 01-11-2022
By Stock market mentor Stock market mentor • 01-11-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
By GuruFocusNews GuruFocusNews • 04-26-2022
By Don Li2 Don Li2 • 11-04-2021
By sperokesalga sperokesalga • 02-22-2023
By GuruFocusNews GuruFocusNews • 05-17-2022
By sperokesalga sperokesalga • 05-10-2023
By Marketwired • 10-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.